Add this topic to your myFT Digest for news straight to your inbox
Pharma group wants to counter rise in drug-resistant infections by developing incentivising model
R&D move aims to convince investors new products will offset decline in respiratory medicines
Chilly reception and political risks of UK deal overcame US group’s appetite for ‘inversion’ deal
Drugmaker says restructuring is ahead of schedule and new products are gaining momentum
Industry faces challenge to become less dependent on key market as pressure grows to cut costs
Outcry over a 5,000% price rise has rattled stocks and hardened opinion for change on pricing models
Test results do not prove effectiveness of asthma medicine to tackle smokers’ cough
New executive group to assist No 10 in run-up to EU referendum
Deal with Shanghai-based Desano suggests UK group is beginning to rebuild its reputation
Develop leaders long before they are required
Shareholders willing for now to allow chief executive to carry out contentious turnround plan
Witty warns ‘poor choices’ being made and not all medicines being snapped up will pay off
In an interview, Andrew Witty, GSK’s embattled chief executive makes the case for his new strategy
Sir Andrew Witty has withdrawn from anti-cancer therapies to grow non-drugs side
Hampton issues public vote of confidence in Whitty but acknowledges weak performance
Andrew Witty is making the right calls, but growth prospects remain tenuous
UK pharma group promises to hold dividend steady for the next three years
UK drugmaker prepares to update investors on R&D pipeline
Witty pays price for falling sales and corruption woes
UK drugs group attempts to reverse fortunes in its most important market
Drugmaker beats expectations as respiratory business struggles
A board’s propensity to sack at first whiff of trouble can do real harm
Changes must be made to the way b-schools are structured and the skills demanded of their staff
Pharma group decides not to pursue divestment despite receiving significant interest in the assets
International Edition